張世彥醫生 - 病理學
病理學專科醫生
重點資料
- 醫務委員會註冊已驗證
- 1 個診所地點九龍塘
- 病理學專科醫生香港中文大學內外全科醫學士 · 香港病理學專科學院院士 · 香港醫學專科學院院士（病理科） · 2005 年醫科畢業
- 保險計劃資料整理中｜查看詳情
關於醫生
張世彥醫生是九龍塘的病理學醫生。
學歷
地點
保險計劃
常見問題
張世彥醫生好嗎？
張世彥醫生是九龍塘的病理學醫生。資歷及註冊資料來自香港醫務委員會。ok.med 不評分，也不排名。
張世彥醫生是做什麼的？
張世彥醫生是病理學醫生。
張世彥醫生在哪裡看診？
張世彥醫生於香港浸信會醫院應診。
研究及論文
共 17 篇，顯示最近 12 篇
按論文主題篩選
主題由同一批 PubMed 論文的醫學分類整理，不代表醫生提供相關診治服務。
- INSM1 is a novel prognostic neuroendocrine marker for luminal B breast cancer.Pathology · 2021
- Combined SOX10 GATA3 is most sensitive in detecting primary and metastatic breast cancers: a comparative study of breast markers in multiple tumors.Breast cancer research and treatment · 2020
- Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.Histopathology · 2020
- The Clinical Significance of Neuroendocrine Features in Invasive Breast Carcinomas.The oncologist · 2020
- Co-expression of HLA-I loci improved prognostication in HER2+ breast cancers.Cancer immunology, immunotherapy : CII · 2020
- Improved Prognostication for the Updated AJCC Breast Cancer Pathological Prognostic Staging Varied in Higher-Stage Groups.Clinical breast cancer · 2020
- Predicting Outcome in Mammary Phyllodes Tumors: Relevance of Clinicopathological Features.Annals of surgical oncology · 2019
- GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.Breast cancer research and treatment · 2018
- Association of clinicopathological features and prognosis of TERT alterations in phyllodes tumor of breast.Scientific reports · 2018
- CD147 expression is associated with poor overall survival in chemotherapy treated triple-negative breast cancer.Journal of clinical pathology · 2018
- Amyloid Precursor Protein Is Associated with Aggressive Behavior in Nonluminal Breast Cancers.The oncologist · 2018
- Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.The oncologist · 2017
論文資料來自 PubMed／Europe PMC，按姓名及機構自動配對；每項均可按連結核對。
僅供參考，不構成醫療建議。 閱讀完整免責聲明